GoldenBiotech Antroquinonol Phase 2 NSCLC Clinical Trial Presents Brilliant Results in ASCO Meeting
Exhibitor: GOLDEN BIOTECHNOLOGY CORP.
Booth No.: L632A
Welcome ! Visit us at L 632A for more new advanced progress info in different indications and therapy.
( Cancer, Tumor, Oncogenic, Ras gene, Cardiovascular , Metabolic disorder, Hyper-lipid and cholesterol, Auto immune
disorder, Neuro-degeneration, Dementia , Alzheimer's Disease etc. )
#Golden Biotechnology Corp.'s Antroquinonol Phase 2 NSCLC Clinical Study Presents Brilliant Results in ASCO Meeting Abstract
ASCO Meeting Abstract : Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer ( NSCLC ) who have failed at least two lines of anti-cancer therapy.
Meeting: 2019 ASCO Annual Meeting
Session Title: Lung Cancer—Non-Small Cell Metastatic: Publication Only
Track:Lung Cancer—Non-Small Cell Metastatic
Subtrack: Metastatic Non-Small Cell Lung Cancer
Abstract #: e20522
Clinical Trial Registry Number:NCT02047344
Citation:J Clin Oncol 37, 2019 (suppl; abstr e20522)
Ching-Liang Ho, David S. Ettinger, Pei-Ni Chen, Howard Cheng, Wu-Che Wen, Shang-Yin Wu, Thierry Marie Jahan, Mary J. Fidler, Bradley Walter Lash, Igor I. Rybkin, Natalie Stanton; Division of Hematology and Oncology, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Golden Biotechnology Corporation, New Taipei City, Taiwan; Golden Biotechnology Corp., New Taipei City, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; University of California San Francisco, San Francisco, CA; Rush University Medical Center, Chicago, IL; Guthrie Clinic, Sayre, PA; Henry Ford Cancer Institute, Detroit, MI; Arizona Clinical Research Center, Tucson, AZ
Background:The aim of this study was to assess the efficacy of Antroquinonol in patients with stage IV NSCLC after failure in two-lines of anti-cancer therapy.
Patients with stage IV non-squamous NSCLC who have failed at 2-4 lines of anti-cancer therapy( chemo + target therapy ) were eligible, though early stage or naïve patients may voluntarily participate. A maximum of 30 evaluable patients were to receive Antroquinonol 600mg per day, of which 15 patients were to be KRAS-positive and 15 patients KRAS negative. The primary endpoint of the study was progression-free survival from the start of treatment to week 12 with disease control rate and overall survival as key secondary endpoints.
There were 31 patients enrolled with evaluable population 30 patients, of which 15 patients were KRAS positive and 15 patients KRAS negative. 73% were with at least two prior chemotherapy. The median PFS of 7 patients with 2 prior chemotherapy was 22.9 weeks (95% confidence interval [CI]: 5.0, 31.1); and 11 patients with more than 2 prior chemotherapy was 11.9 weeks (95% confidence interval [CI]: 6.0, 14.1), with a 1-year PFS of 11.4%. Of 11 patients who had had more than 2 prior chemotherapy, the median OS was 47.3 weeks (95% CI: 14.1,-), with a 1-year OS of 39.3%, and the overall disease control rate was 72.7%, with 100% in KRAS negative and 50% in KRAS positive. No systemic toxicities were observed.
The monotherapy of Antroquinonol brought up higher disease control rates and longer progression-free survival and overall survival, compared with historical data. Although KRAS negative shows much better than KRAS positive group, Antroquinonol still work well with KRAS positive patients. Clinical trial information: NCT02047344
#Antroquinonol (Hocena ), #Golden Biotechnology Corporation(TW4132) , #GoldenBiotech
Golden Biotechnology Corp. homepage:
Welcome visit us at L 632A for more new advanced progress info in different indications and therapy. ( Cancer, Tumor, Oncogenic, Ras gene, Cardiovascular , Metabolic disorder, Hyper-lipid and cholesterol, Auto immune disorder, Neuro-degeneration, Dementia , Alzheimer's Disease etc. )
More Exhibitor's Press Release
- The Secret of Deep Sea｜Bioyona TEKHO MARINE BIOTECH CO., LTD. / 2019-09-12
- The only ingredient for the fucoidan National Health Food “Mai-Hai-Yun” - Okinawa fucoidan FF-36 KANWA HEALTHCARE LTD. / 2019-08-15
- Masterasia is your first choice: Functional food materials supply, and Bar ODM/OEM services MASTERASIA MARKETING CO., LTD / 2019-07-27
- New Solution for Chronic Disease -″Anti-Hypoxia Medical Theory & Oxygener Bio-Chip″ G-SYN BIOMEDICAL TECHNOLOGY INC. / 2019-07-26
- Agri-Dragon Biotech specializes in innovating farming technology and promotes circular economy AGRI-DRAGON BIOTECH CO., LTD. / 2019-07-25
- Winnoz Looks For Global Partners for Haiim™ - A Unique Blood Micro-sampling Device at BioAsia Taiwan WINNOZ TECHNOLOGY INC / 2019-07-24
- The Brand New Exclusive Skincare Ingredients of Global Beauty TEKHO MARINE BIOTECH CO., LTD. / 2019-07-23
- INORA─『Best Quality, Leading Technology and Best Service』 INORA PHARMACEUTICAL MACHINERY CO., LTD. / 2019-07-23
- Insilico Medicine to present at the 2019 Bio Asia-Taiwan INSILICO TAIWAN LTD. / 2019-07-21
- Head to Europe! Invitrx runs global collaboration in 30 countries INVITRX THERAPEUTICS, INC. / 2019-07-19
- Phytoitalia presents two new ingredients for nutraceutical/cosmetic purposes with clinical studies PHYTOITALIA SRL / 2019-07-16
- Synmax provides comprehensive services in fermentation from laboratory to commercial production SYNMAX BIOCHEMICAL CO., LTD. / 2019-07-15
- Are you worrying falling? Easy Safe Protector you...... YI AN MEDICAL EQUIPMENT CO ., LTD. / 2019-07-11
- BioAsia Special 10% Off Coupon Campaign TOKYO FUTURE STYLE, INC / 2019-07-10
- Taiwan Health Club Provides Premarket Services HEALTH CLUB OF TAIWAN / 2019-07-10
- Univercells granted $14.3M to deliver affordable measles & rubella vaccines UNIVERCELLS / 2019-07-09
- The Best Food Supplement-Himematsutake/SOSORO 100% Herbal Oral Rinse FUJI INTERNATIONAL ENTERPRISES / 2019-07-09
- Medical products -NMPA (CFDA) registration service in mainland China BEIJING HENGXIN BOEN MEDICAL TECHNOLOGY CO., LTD / 2019-07-08
- TFBS Bioscience service items TFBS BIOSCIENCE, INC. / 2019-07-05
- EURONATIONAL owns a complete portfolio with innovative solutions and natural effective formulations. EURONATIONAL SRL / 2019-07-04